NEW YORK – T2 Biosystems said on Monday that it plans to outlicense its proprietary technology for the detection of sepsis-causing pathogens in whole-blood samples.
The Lexington, Massachusetts-based firm said that its T2 Magnetic Resonance technology for the detection of pathogens directly from whole blood could be adapted for use with fluorescence and other testing methods. Under potential licensing agreements, the technology could be used in additional testing platforms to detect pathogens and markers of antibiotic resistance.
"This new strategy further leverages our robust patent portfolio and scientific expertise to accelerate our mission to improve patient outcomes, lower mortality rates, and reduce healthcare cost by enabling clinicians to make faster, targeted antimicrobial decisions," T2 CEO John Sperzel said in a statement.
T2 said the technology is a key component of its US Food and Drug Administration-cleared instruments and tests, and it plans to generate non-dilutive capital through revenue streams from royalties. The firm noted that its T2Dx Instrument, T2Bacteria Panel, and T2Candida Panel are used for the detection of sepsis-causing bacterial and fungal pathogens without a positive blood culture, with results in three to five hours.
T2 received FDA clearance for the use of its Candida test in pediatric patients in September. The company also said that month that the European Patent Office had upheld one of the company's European patents for a direct-from-whole-blood pathogen detection method, despite opposition from BioMérieux and other undisclosed firms.